Newsspaper Cutting for Financial Results
Annual Secretarial Compliance Report for FY 2025-2026
Company has not entered any Related Party Transactions during the half year ended 31st March, 2026
Statement of Deviation or Variation in ultilization of Funds under Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is not applicable to the Company for the quarter ended 31st March, 2026
Audited Financial Results for 31st March, 2026
Outcome of Board Meeting for Audited Results for 31st March, 2026
Intimation of Board Meeting to be held on 22nd May 2026 for the quarter and year ended 31st March 2026
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company Bacil Pharma Ltd 2 CIN NO. L24200MH1987PLC043427 3 Report filed for FY 2025-2026 Details of the Current block (all figures in Rs crore): 4 2 – year block period (Specify financial years)* 2023-24, 2024-25 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T – 1) carried forward to FY (T) (d) 0 8Quantum of (d), which has been met from (c)(e)* 0 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T – 1) which was carried forward to FY(T)}(f) = (b) – [(c) – (e)]{ If the calculated value is zero or negative, write “nil”}* 0 Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 – year Block period (Specify financial years)2023-24, 2024-25 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) – (e)}#0.00 Name of the Company Secretary :-Dikshant Singh PanwarDesignation :-Company Secreatary Name of the Chief Financial Officer :- Chaitali Kalpataru Shah Designation : -Director Date: 27/04/2026